FDA Clears MMI to Expand Symani Alzheimer’s Trial

The US FDA has cleared Medical Microinstruments (MMI) to expand its REMIND early feasibility study of robotic microsurgery for Alzheimer’s disease, allowing enrolment to increase from up to five patients to 15. Announced on 30 July 2026, the trial evaluates use of MMI’s Symani robotic system to re-establish drainage pathways in the deep cervical lymph nodes of patients with mild to moderate Alzheimer’s disease and confirmed lymphatic abnormalities.

The theory underpinning the REMIND study is that restoring drainage pathways in the deep cervical lymph nodes can help clear neurotoxins from the brain, including amyloid beta and phosphorylated tau, which researchers believe contribute to Alzheimer’s disease progression. The FDA approved a supplement to MMI’s investigational device exemption after reviewing 30-day safety data for the initial patients treated. The first patient underwent the procedure at Baptist Health in Jacksonville, Florida, in May 2026.

Symani is the only commercially available robotic system designed for microsurgery, allowing surgeons to reconnect and repair blood and lymphatic vessels under a millimetre in diameter by filtering out tremors and translating hand and wrist motions into scaled-down movements of miniaturised instruments. The system received FDA de novo classification for microsurgery in 2024, with a 2025 clearance expanding capabilities to include soft tissue dissection. MMI CEO Mark Toland described the Alzheimer’s procedure as pushing the boundaries of medicine. Symani is also used for reconstructive head and neck procedures in cancer patients, cochlear implants, ophthalmic procedures, intracranial brain surgery, liver transplantation and spine tumour removal.

The commercial signal is a novel intersection of surgical robotics and Alzheimer’s therapy at a moment when amyloid-clearing drugs are still delivering modest clinical impact. If restoration of cervical lymphatic drainage translates to meaningful clinical benefit, MMI’s Symani becomes the anchoring platform for an entirely new procedural category. Expect Intuitive Surgical, Medtronic and Stryker to monitor closely as they consider microsurgical adjacencies.

For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough treatments, industry trends, and regulatory news, contact Amelia Phillips today!